Massachusetts is currently home to 3148 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
NCT04669171
Recruiting
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Follicular Lymphoma, Marginal Zone Lymphoma
Register for Updates
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab
NCT04130516
Recruiting
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combination with pembrolizumab. The study will include a dose escalation phase, a dose expansion phase, and phase 2A cohorts. Up to 200 patients will be accrued for this study. Up to 15 study sites in the United States will participate in the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Solid Tumor, Adult
Register for Updates
Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study
NCT06654895
Recruiting
The primary objective of this study is to validate a pre-defined IL-6 concentration cutoff that predicts 28-day mortality in patients who are admitted or are intended to be admitted to the ICU diagnosed with sepsis or septic shock.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
12/09/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Sepsis, Septic Shock
Register for Updates
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis
NCT06429176
Recruiting
The goal of this clinical trial is to learn if drug SPL84 is safe for adult patients with cystic fibrosis (CF). It will also learn if the drug works to treat works to treat CF with a specific mutation. The purpose of this research study is to: * test the safety and effectiveness of multiple doses of the study drug, SPL84 * test how multiple doses of the drug are processed by the body Researchers will compare drug SPL84 to a placebo (a look-alike substance that contains no drug) to see if drug... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Boston Children'S Hospital, Boston, Massachusetts
Conditions: Cystic Fibrosis
Register for Updates
A Registry for People With T-cell Lymphoma
NCT05978141
Recruiting
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.
Gender:
ALL
Ages:
All
Trial Updated:
12/09/2024
Locations: Massachusetts General Hospital (Data Collection Only), Boston, Massachusetts
Conditions: T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma
Register for Updates
Niraparib in Tumors Metastatic to the CNS
NCT04992013
Recruiting
This research is being done to see how effective the drug niraparib is against cancer that has metastasized to the central nervous system (CNS). * This research study involves the study drug niraparib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Metastatic Cancer, Central Nervous System Cancer
Register for Updates
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
NCT04098445
Recruiting
Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary morbidity affects as many as 25% of children receiving transplant. Early pulmonary injury includes diffuse alveolar hemorrhage (DAH), thrombotic microangiopathy (TMA) interstitial pneumonitis (IPS) and infection, while later, bronchiolitis obliterans is a complication of chronic GVHD associated with severe morbidity and mortality. Improved diagnosis and treatment of pulmonary complications are urgently need... Read More
Gender:
ALL
Ages:
24 years and below
Trial Updated:
12/09/2024
Locations: Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, Massachusetts
Conditions: Hematopoietic Stem Cell Transplant (HSCT), Diffuse Alveolar Hemorrhage, Thrombotic Microangiopathies, Interstitial Pneumonitis, Bronchiolitis Obliterans
Register for Updates
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
NCT04047628
Recruiting
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be followed for 72 months after randomization (Day 0, Visit 0).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/09/2024
Locations: University of Massachusetts Memorial Medical Center, Worcester, Massachusetts
Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Register for Updates
Multicenter Evaluation of Near Vision and Outdoor Time in Kids Study
NCT06119243
Recruiting
Currently, optical and pharmacological interventions have been developed to prevent the progression of childhood myopia. However, no myopia control strategy has been shown to have complete efficacy in controlling myopia progression in children. One possible reason is that risk factors contributing to the development of myopia were not controlled in previous clinical studies including time outdoors and near vision behaviour. This study aims to quantify time spent outdoors and near vision behavior... Read More
Gender:
ALL
Ages:
Between 4 years and 14 years
Trial Updated:
12/08/2024
Locations: New England College of Optometry, Boston, Massachusetts
Conditions: Myopia
Register for Updates
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
NCT05668962
Recruiting
This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/07/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer, Follicular Thyroid Cancer, Unresectable Thyroid Gland Carcinoma, Papillary Thyroid Cancer
Register for Updates
Intervention for Fatigue in HCT Recipients
NCT05715047
Recruiting
The purpose of this study is to assess whether a cognitive-behavioral therapy (CBT) for fatigue intervention is acceptable, feasible, and effective at managing fatigue and improving quality of life for patients following hematopoietic stem cell transplant (HCT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Hematologic Cancer, Hematologic Malignancy
Register for Updates
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
NCT05577819
Recruiting
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify a... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
12/06/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Transthyretin Amyloidosis, Heart Failure, Heart Failure, Diastolic, Amyloidosis
Register for Updates